Exhibit 10.1

 

CONFIDENTIAL TREATMENT REQUESTED

Portions of this Exhibit have been redacted pursuant to a request for
confidential treatment under Rule 24b-2 of the General Rules and Regulations
under the Securities Exchange Act of 1934, as amended. Omitted information,
marked “[*]” in this Exhibit, has been filed separately with the Securities and
Exchange Commission together with such request for confidential treatment.

 

AMENDMENT #14

TO LICENSE AGREEMENT ID LA0003Endocyte

Between Purdue Research Foundation and Endocyte Corporation

 

THIS AMENDMENT, made and entered into this 30'" day of January, 20 I 5 ("Amendment Effective Date") amends the Amended and Restated License Agreement executed on October 21st, 1998, and all subsequent Amendments (hereinafter AGREEMENT)
between Purdue Research
Foundation (hereinafter known as PRF) and Endocyte Corporation (hereinafter known as LICENSEE) with respect to the matters
addressed in this Agreement.

 

NOW THEREFORE, the patties hereto do hereby agree as follows:

 

1.
  The technology, "Folate-Based Chimeric Antigen Receptor (CAR) T-Cells as Anti-Cancer Therapeutics" PRF Reference No. 66212 is added to Append ix A of the AGREEMENT.

 

2.   The following Patents are added to Appendix A of the Agreement:

 

/

 

 

 

 

 

 

PRF Ref.

No.

Application #

Status

Type

Filing Date

Funding

66212-01

61/740,384

Converted

Provisional

12/20/2012

Endocyte

66212-02

PCT/US2013/076986

Published

PCT

12/20/2013

Endocyte

 

 

 

All other terms and conditions of the original agreement remain unchanged and in effect.

 

 

IN WITNESS WHEREOF, the parties hereto have executed this Amendment as of the date first above written.

 

 

 

Purdue Research FoundationEndocyte Corporation

 

[*] = Indicates confidential information omitted and filed separately with the
Securities and Exchange Commission pursuant to a request for confidential
treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.

 

--------------------------------------------------------------------------------

 

  By: __/s/ Frank Razavi____By: __/s/ P. Ron Ellis_____

 

 

  Frank RazaviP. Ron Ellis

  Acting Director, Corporate & New VenturesPresident/CEO

  OTC

 

 

  Date: _2-17-2015_________Date: _11 Feb 2015________

[*] = Indicates confidential information omitted and filed separately with the
Securities and Exchange Commission pursuant to a request for confidential
treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.

 

--------------------------------------------------------------------------------

 

 

 

 

AMENDMENT #15

TO LICENSE AGREEMENT ID LA0003Endocyte

 

Between Purdue Research Foundation and Endocyte Corporation

 

 

THIS AMENDMENT, made and entered into this 20th
day of May, 2015 ("Amendment Effective Date") amends the Amended and Restated License Agreement executed on October 21st
 , 1998,
and all subsequent Amendments (hereinafter AGREEMENT) between Purdue Research Foundation (hereinafter known as PRF) and Endocyte Corporation (hereinafter known as LICENSEE) with respect to the matters addressed in this Agreement.

 

NOW THEREFORE, the parties hereto do hereby agree as follows:

 

l. The Eligible Disclosure, "Discovery of Synergy Between Folate-hapten Mediated

Immunotherapy and Receptor Tyrosine Kinase (rtk) Inhibitors for the Treatment of Cancers" PRF
Reference No. 66939 is added to Appendix A of the AGREEMENT.

 

 

 

All other terms and conditions of the original agreement remain unchanged and in effect.

 

 

 

IN WITNESS WHEREOF, the parties hereto have
executed this Amendment as of the date first above written.

 

 

 

Purdue Research FoundationEndocyte Corporation

 

 

By: ___/s/ Chad A. Pittman__            By: __/s/ P. Ron Ellis________

 

 

Chad A. PittmanP. Ron Ellis

Vice PresidentPresident/CEO

 

 

 

[*] = Indicates confidential information omitted and filed separately with the
Securities and Exchange Commission pursuant to a request for confidential
treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.

 

--------------------------------------------------------------------------------

 

 

Date: ___1 June 2015______Date: ___29 May 2015______

[*] = Indicates confidential information omitted and filed separately with the
Securities and Exchange Commission pursuant to a request for confidential
treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.

 

--------------------------------------------------------------------------------

 

 

AMENDMENT #16

TO LICENSE AGREEMENT ID LA0003Endocyte

 

Between Purdue Research Foundation and Endocyte Corporation

 

THIS AMENDMENT, made and entered into this 4th day of June, 2015 ("Amendment Effective Date") amends the Amended and Restated
License Agreement executed on October 21st,  1998, and all subsequent
 amendments (hereinafter AGREEMENT) between Purdue Research Foundation (hereinafter known as PRF) and Endocyte, Incorporated (hereinafter known as LICENSEE) with respect to the matters addressed in this
agreement.

 

NOW THEREFORE, the parties hereto do hereby agree as follows:

 

1.  The Eligible Disclosures, "Endosomal Escape" PRF Reference No. 65668 and PRF Ref. No.

67126 "A New Mechanism for Release of Endosomal Contents: Osmotic Disruption of Endosomes Via Nigericin-Mediated Potassium-Hydrogen Ion Exchange" have been combined and filed in US 62/159,659 and are added to Appendix A of the AGREEMENT.

 

 

 

 

All other terms and conditions of the original agreement remain unchanged and in effect.

 

 

IN WITNESS WHEREOF, the parties hereto have executed this Amendment as of the date first above written.

 

 

 

Purdue Research FoundationEndocyte, Incorporated

 

   By: ___/s/ Chad A. Pittman     By: ____P. Ron Ellis____

 

 

  Chad A. PittmanP. Ron Ellis

   Vice PresidentPresident/CEO

 

 

   Date: __July 28, 2015_____Date: ___June 17, 2015______

[*] = Indicates confidential information omitted and filed separately with the
Securities and Exchange Commission pursuant to a request for confidential
treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.

 

--------------------------------------------------------------------------------

 

 

AMENDMENT #17

TO LICENSE AGREEMENT ID LA0003Endocyte

 

Between Purdue Research Foundation and Endocyte Corporation

 

THIS AMENDMENT,
 made and entered into this 24th day of June, 2016 ("Amendment Effective Date") amends the Amended and Restated License Agreement executed on October 21st, 1998, and all subsequent
 Amendments  (hereinafter AGREEMENT)  between  Purdue Research
 Foundation (hereinafter known as PRF) and Endocyte, Inc. (hereinafter known as LICENSEE) with respect to the matters addressed in this Agreement.

 

NOW THEREFORE, the parties hereto do hereby agree as follows:

 

1.  The following Eligible Disclosure is added to Appendix A of the AGREEMENT:

 

 

 

Title of Eligible Disclosure:

[*] 

PRF Reference Number for Eligible Disclosure:

[*]

Contributors of the Eligible Disclosure:

[*]

 

 

2.   The following Licensed Patents are added to Appendix A of the Agreement:

 

 

 

 

 

 

 

 

 

 

PRF

Reference

No.

Title of Application

Serial Number

Inventors

Filling Date

Country

Status

[*]

[*] 

[*]

[*]

[*]

[*]

[*]

[*] = Indicates confidential information omitted and filed separately with the
Securities and Exchange Commission pursuant to a request for confidential
treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.

 

--------------------------------------------------------------------------------

 

 

 

 

All other
terms and conditions of the original agreement remain unchanged and in effect.

 

 

 

 

 

 

IN WITNESS WHEREOF, the parties hereto have executed this Amendment as of the
Amendment Effective Date.

 

 

Purdue Research FoundationEndocyte, Inc.

 

 

By: ____/s/ Emily G. Najem____By: __/s/ Mike Sherman_______________

 

Name: _____ Emily G. Najem __________               Name: ___Mike Sherman_______

 

Title: ______Corporate Counsel_________Title: ___ CEO____

 

 

[*] = Indicates confidential information omitted and filed separately with the
Securities and Exchange Commission pursuant to a request for confidential
treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.

 

--------------------------------------------------------------------------------

 

 

AMENDMENT #18

TO LICENSE AGREEMENT ID LA0003Endocyte

 

Between Purdue Research Foundation and Endocyte Corporation

 

THIS AMENDMENT, made and entered into this 24th day of June, 20 16 ("Amendment Effective Date") amends the Amended and Restated License Agreement executed on October 21,1998, and all subsequent
Amendments (hereinafter AGREEMENT) between Purdue Research Foundation (hereinafter known as PRF) and Endocyte, Inc.
(hereinafter known as LICENSEE) with respect
to the matters addressed in this Agreement.

 

NOW THEREFORE, the parties hereto do hereby agree as follows:

 

1.  The following Eligible Disclosure is added to Appendix A of the AGREEMENT:

 

 

 

Title of Eligible Disclosure:

Method of Treating Cancer by Targeting Tumor-Associated   Macrophages

PRF Reference Number for Eligible Disclosure:

67565

Contributors of the Eligible Disclosure:

Philip S. Low -Purdue University Yingjuan Lu - Endocyte, Inc.

Leroy Wheeler - Endocyte, Inc. Christopher Leamon -Endocyte, Inc.

 

 

2.  The following Licensed Patents are added to Appendix A of the Agreement:

 

 No.

 

 

 

 

 

 

 

PRF

Reference No.

Title of Application

Serial Number

Inventors

Filling Date

Country

Status

67565-03

Methods of Treating Cancer by Targeting Tumor- Associated Macrophages

PCT/US2 015/06239

5

Philip S. Low Yingjuan Lu Leroy Wheeler Chris

Leamon

11-24-15

WO

Filed

 

 

[*] = Indicates confidential information omitted and filed separately with the
Securities and Exchange Commission pursuant to a request for confidential
treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.

 

--------------------------------------------------------------------------------

 

 

All other terms and conditions of the original agreement remain unchanged and in effect.

 

 

 

 

 

 

 

 

IN WITNESS WHEREOF, the parties hereto have executed this Amendment as of the
Amendment Effective Date.

 

Purdue Research Foundation

 

Endocyte, Inc.

By:         /s/ Emily G. Najem                               

 

By:       /s/ Mike Sherman                                             

Name:    Emily G. Najem                             

 

Name: Mike Sherman                                             

Title:      Corporate Counsel                         

 

Title:  CEO                                                              

 

[*] = Indicates confidential information omitted and filed separately with the
Securities and Exchange Commission pursuant to a request for confidential
treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.

 

--------------------------------------------------------------------------------

 

 

 

AMENDMENT #19

TO LICENSE AGREEMENT ID LA0003Endocyte

 

Between Purdue Research Foundation and Endocyte Corporation

 

THIS AMENDMENT, made and entered into this 21st day of February, 2017
(“Amendment Effective Date”) amends the Amended and Restated License Agreement
executed on October 21st, 1998, and all subsequent Amendments (hereinafter
AGREEMENT) between Purdue Research Foundation (hereinafter known as PRF) and
Endocyte, Inc. (hereinafter known as LICENSEE) with respect to the matters
addressed in this Agreement.

 

NOW THEREFORE, the parties hereto do hereby agree as follows:

 

1.

The technology, “Folate-Based Chimeric Antigen Receptor (CAR) T-Cells as
Anti-Cancer Therapeutics” PRF Reference No. 66212 (“Technology”) and all license
and patent rights of the Technology granted under the AGREEMENT are terminated.

2.

The following Patents are removed from Appendix A of the AGREEMENT:

 

 

 

 

 

 

 

 

PRF Ref #

Title of Application

Application Number

Inventors

Filing Date

Country

Status

66212-01

Adoptive Cell Therapy Using Chimeric Antigen Receptor expressing T Cells for the
Treatment of Cancers

61/740,384

P. Low

Dec. 20, 2012

United States (Provisional)

Converted

66212-02

CHIMERIC ANTIGEN RECEPTOR-EXPRESSING T CELLS AS ANTI-CANCER THERAPEUTICS

PCT/US2013/076986

P. Low, H. Chu, and Y. Lee

Dec. 20, 2013

PCT

Nationalized

 

 

 

3.

All other terms and conditions of the AGREEMENT remain unchanged and in effect.

[*] = Indicates confidential information omitted and filed separately with the
Securities and Exchange Commission pursuant to a request for confidential
treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.

 

--------------------------------------------------------------------------------

 

 

 

 

 

IN WITNESS WHEREOF, the parties hereto have executed this Amendment as of the
Amendment Effective Date.

 

Purdue Research FoundationEndocyte, Inc.

By: _____/s/ Emily G. Najem______By: ___/s/ Mike Sherman____

Name: ____ Emily G. Najem _____Name: ___ Mike Sherman _______

 

Title: _____Corporate Counsel ______Title: _____President and CEO__

 

 

 

 

 

[*] = Indicates confidential information omitted and filed separately with the
Securities and Exchange Commission pursuant to a request for confidential
treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.

 

--------------------------------------------------------------------------------